Screener
Immunome IMNM Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Immunome’s reported figures.
Based on the most recent quarter.
The source filing: Immunome’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
FAQ
- What is Immunome's debt-to-equity?
- Immunome (IMNM) reported debt-to-equity of 0× in Q1 2026.
- How has Immunome's debt-to-equity changed year-over-year?
- Immunome's debt-to-equity decreased by 59.4% year-over-year, from 0× to 0×.
- What is the long-term trend for Immunome's debt-to-equity?
- Over 4 years (2020 to 2025), Immunome's debt-to-equity has grown at a -15.7% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Immunome's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude